Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313,